Free text responses indicated participants experienced some trepidation before their interviews but had a positive experience overall and valued the professionalism/supportiveness of the study team and the opportunity to use their experience/insights to contribute to research
Whats Coming Orforglipron, Lillys oral GLP-1 (non-peptide), is in late-phase trials
Efectos gastrointestinales: Las nuseas son el efecto secundario ms comn, con tasas que varan segn el producto especfico y la dosis (las tasas pueden oscilar entre 15-40% segn la informacin de prescripcin de la FDA para diferentes productos)
374 Liraglutide can directly enhance bone formation in the MC3T3-E1 osteoblastic cell line
Allulose is a dietary sweetener with minimal metabolic effects, while GLP-1 agonists are FDA-approved prescription drugs with proven efficacy for type 2 diabetes management and cardiovascular benefits
Borgiani G, Possidente C, Fabbri C, Oliva V, Bloemendaal M, Arias Vasquez A, et al
